Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600535 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
A Phase 1 study, sponsored by Cougar Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00600535 is a Phase 1 study that has completed, run by Cougar Biotechnology. The registered enrollment target is 31 participants.
The verdict
NCT00600535, a Phase 1 study, has completed, sponsored by Cougar Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
Interventions
- DRUG Stage 1 Group 1: abiraterone acetate
- DRUG Stage 1 Group 2: abiraterone acetate
- DRUG Stage 2: abiraterone acetate
- DRUG Stage 3: abiraterone acetate
- DRUG Stage 3: glucocorticoid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-07 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600535
The ClinicalTrials.gov registry entry for NCT00600535 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cougar Biotechnology, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Stage 1 Group 1: abiraterone acetate is the first listed.
NCT00600535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600535 about?
NCT00600535 is a clinical study titled "A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer". The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of capsule and tablet formulations of CB7630 (abiraterone acetate) taken with and without food in patients with prostate cancer.
What is the current status of trial NCT00600535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-07. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00600535?
The interventions under investigation include: Stage 1 Group 1: abiraterone acetate (DRUG), Stage 1 Group 2: abiraterone acetate (DRUG), Stage 2: abiraterone acetate (DRUG), Stage 3: abiraterone acetate (DRUG), Stage 3: glucocorticoid (DRUG).
Who is sponsoring clinical trial NCT00600535?
This trial is sponsored by Cougar Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.